Navigation Links
Arbor Vita rapid H5N1 flu diagnostic presented at ICEID meeting
Date:3/27/2008

Sunnyvale, CA March 27, 2008 Preliminary research from the Department of Respiratory Disease Research at the Naval Health Research Center (NHRC) suggests that a rapid antigen assay test developed by Arbor Vita Corporation (AVC) shows promise as a useful diagnostic for the detection of the avian influenza virus in humans. Researchers from NHRC reported their findings last week at the 2008 International Conference on Emerging Infectious Diseases (ICEID) in Atlanta, Georgia.

The AVC test differs from other rapid-antigen assays in that it detects the NS1 protein, as opposed to the nucleoprotein (NP). Antigen capture is mediated through a PDZ protein, which binds the C-terminal region of the NS1 protein. As the C-terminal region of the NS1 protein differs for each influenza sub-type, a PDZ protein with high affinity to NS1 protein of H5 strains was chosen for assay development.

The format of the developed assay is the familiar lateral-flow rapid antigen assay. However, the role of the capture antibody is performed by a PDZ protein, which provides superior specificity and binding affinity. Lateral flow assays have several advantages that make them appealing for field deployment and far-forward mission use. These include: ease of use, time to results, cost, lack of cold-chain requirements and portability.

NHRCs archive of respiratory pathogens was used to evaluate the performance of the AVC avian influenza diagnostic against clinical samples. Two hundred samples from two years of surveillance were tested with the assay following procedures provided by AVC.

In addition, NHRC collaborated with Naval Medical Research Unit 3 (NAMRU3), located in Cairo, Egypt. NAMRU3, which is the WHO collaborating site for the African continent and Middle East region, has conducted surveillance for highly pathogenic avian influenza in wild and domestic birds, as well as human populations and has access to isolate H5N1 material. Twenty-eight different H5N1 isolates from avian and human sources were tested with the AVC assay. Results of the AVC assay were presented at ICEID that showed no false positives against the respiratory clinical panel. Of the 28 H5N1 cultures tested, 26 gave positive results on the assay (sensitivity = 93%).

The researchers concluded that the PDZ based assay produced by AVC shows promise as a useful diagnostic in our vigilance against avian influenza. The sensitivity of the assay towards avian strains is robust and the format of the test favors easy deployment. NHRC and NAMRU3 will continue to collaborate to evaluate this assay against other grown strains (H7, H9 etc.) as well as in actual outbreak situations.


'/>"/>

Contact: Debra Bannister
530-676-8001
Arbor Vita Corporation
Source:Eurekalert

Related biology news :

1. Coral reef fish harbor an unexpectedly high biodiversity of parasites
2. From brains to behavior: Cold Spring Harbor Protocols features methods for neuroscience research
3. Cold Spring Harbor Protocols highlights a method that captures cell growth and activity
4. Cold Spring Harbor Laboratorys lung cancer research program awarded $100,000 grant
5. Cold Spring Harbor Laboratory to play central role addressing key questions in plant biology
6. RNA-based methods for developmental studies are featured in Cold Spring Harbor Protocols
7. San Diego Harbor Police Deploy BIO-key(R) Automated Vehicle Location System
8. Popular apple variety harbors unusual cell growth
9. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
10. New decontamination system kills anthrax rapidly without lingering effects
11. New chemically-sensitive MRI scan may bypass some invasive diagnostic tests in next decade
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2016)... SAN JOSE, Calif. , Jan. 20, 2016 ... leading developer of human interface solutions, today announced ... touch controller solution for wearables and small screen ... appliances such as printers. Supporting round and rectangular ... the S1423 offers excellent performance with moisture on ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
(Date:1/7/2016)... -- Various factors have contributed to the rise ... and biosimilars. Some of these factors include the ... for cost-effective alternatives, growing burden of chronic diseases, ... of their corresponding patented biologic drugs, and are ... efficacy. The global biosimilars market is estimated to ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016 Australian-US drug discovery ... announced today the appointment of a new Chairman, Mr ... Carmine , effective immediately. James Garner , ... Executive Director and former Acting CEO, Mr Iain Ross ... Non-Executive Director. --> James Garner , has also ...
(Date:2/4/2016)... ... 04, 2016 , ... Shimadzu Scientific Instruments will showcase several ... and poster sessions, and present on the analysis of mycotoxins and medical cannabis ... to 10 at the Georgia World Congress Center in Atlanta, Georgia. , ...
(Date:2/4/2016)... and MENLO PARK, Calif. , Feb. ... ("DelMar" and the "Company"), a biopharmaceutical company focused on the ... it will present at the 18 th Annual ... 2016 at 10:00 a.m. EST in New York, ... president and CEO, will provide an update on the ongoing ...
(Date:2/4/2016)... Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... China , today announced that the ... February 4, 2016 a preliminary non-binding proposal letter, dated ... V-Ming ( Shanghai ) Investment Holdings Co., ... Shenzhen ) Fund Management Co., Ltd., Beijing ...
Breaking Biology Technology: